The role of SLAM/CD2 polymorphisms in systemic autoimmunity

Andrew Wang1, Frederic Batteux, Edward K Wakeland

  • 1Department of Immunology and the Walter M. and Helen D. Bader Center for Research on Arthritis and Autoimmune Disease, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Insights

Polymorphisms in the SLAM/CD2 gene family influence autoimmune disease susceptibility by affecting immune cell development and interactions. These findings highlight the SLAM/CD2 family as a potential target for immunotherapy.

Area of Science:

  • Immunology
  • Genetics
  • Autoimmunity

Background:

  • The SLAM/CD2 gene family encodes crucial receptors for immune system regulation.
  • Polymorphisms in Ly108, Ly9, and CD84 impact susceptibility to systemic autoimmunity in mice and humans.
  • Ly108 polymorphisms affect central tolerance in B and T cell development via apoptosis, anergy, and cell-cycle modulation.

Purpose of the Study:

  • To investigate the role of SLAM/CD2 family members in immune regulation and autoimmunity.
  • To explore the association between B-T cell interactions, germinal center formation, and systemic autoimmunity.
  • To identify potential therapeutic targets for autoimmune diseases.

Main Methods:

  • Analysis of gene polymorphisms in SLAM/CD2 family members.
  • Studies on the impact of Ly108 polymorphisms on T and B cell development.
  • Investigation of SLAM-associated protein (SAP) in B-T cell interactions and germinal center formation.

Main Results:

  • SLAM/CD2 gene family polymorphisms are linked to autoimmune disease susceptibility.
  • Ly108 variations significantly affect central tolerance mechanisms.
  • Ly108, CD84, and SAP are critical for B-T cell interactions during germinal center formation.

Conclusions:

  • The SLAM/CD2 gene family plays a multifaceted role in immune system regulation and autoimmune disease pathogenesis.
  • Impaired B-T cell interactions during germinal center formation may contribute to systemic lupus erythematosus (SLE) susceptibility.
  • The SLAM/CD2 family represents a promising target for novel immunotherapy strategies against autoimmune diseases.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...